PCI Biotech Holding ASA (OSL:PCIB) Beneish M-Score: 0.00 (As of Jul. 04, 2026)

What is PCI Biotech Holding ASA Beneish M-Score?

PCI Biotech Holding ASA OSL:PCIB -12.21% 6 Beneish M-Score is 0.00 as of Jul. 04, 2026. GuruFocus rates OSL:PCIB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for PCI Biotech Holding ASA's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of PCI Biotech Holding ASA was 0.00. The lowest was 0.00. And the median was 0.00.

PCI Biotech Holding ASA Beneish M-Score Related Terms

PCI Biotech Holding ASA Beneish M-Score Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Beneish M-Score Chart

PCI Biotech Holding ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beneish M-Score

Get a 7-Day Free Trial

0.00

PCI Biotech Holding ASA Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25
Beneish M-Score	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

OSL:PCIB vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, PCI Biotech Holding ASA's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Beneish M-Score falls into.

Save Embed

6GF Score

PCI Biotech Holding ASA OSL:PCIB

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PCI Biotech Holding ASA Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of PCI Biotech Holding ASA for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Dec24) TTM:

Last Year (Dec23) TTM:

Total Receivables was kr3.37 Mil.
Revenue was kr0.00 Mil.
Gross Profit was kr0.00 Mil.
Total Current Assets was kr30.91 Mil.
Total Assets was kr31.22 Mil.
Property, Plant and Equipment(Net PPE) was kr0.31 Mil.
Depreciation, Depletion and Amortization(DDA) was kr0.30 Mil.
Selling, General, & Admin. Expense(SGA) was kr8.63 Mil.
Total Current Liabilities was kr7.76 Mil.
Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.
Net Income was kr-16.42 Mil.
Gross Profit was kr0.00 Mil.
Cash Flow from Operations was kr-13.76 Mil.

Total Receivables was kr2.40 Mil.
Revenue was kr0.00 Mil.
Gross Profit was kr0.00 Mil.
Total Current Assets was kr43.75 Mil.
Total Assets was kr44.05 Mil.
Property, Plant and Equipment(Net PPE) was kr0.30 Mil.
Depreciation, Depletion and Amortization(DDA) was kr0.37 Mil.
Selling, General, & Admin. Expense(SGA) was kr9.60 Mil.
Total Current Liabilities was kr4.97 Mil.
Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(3.368 / 0)	/	(2.402 / 0)
	=		/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (30.905 + 0.308) / 31.215)	/	(1 - (43.753 + 0.296) / 44.05)
	=	6.4E-5	/	2.3E-5
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.371 / (0.371 + 0.296))	/	(0.303 / (0.303 + 0.308))
	=	0.556222	/	0.495908
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(8.628 / 0)	/	(9.604 / 0)
	=		/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0 + 7.762) / 31.215)	/	((0 + 4.974) / 44.05)
	=	0.248663	/	0.112917
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-16.417 - 0	-	-13.758)	/	31.215
	=	-0.085183

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of 0.00 mean?

PCI Biotech Holding ASA (OSL:PCIB) has a Beneish M-Score of 0.00 as of Jul. 04, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on PCI Biotech Holding ASA and its competitors.

Is PCI Biotech Holding ASA's Beneish M-Score too high?

PCI Biotech Holding ASA's current Beneish M-Score is 0.00. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.

How does PCI Biotech Holding ASA's Beneish M-Score compare to VRTX and REGN?

PCI Biotech Holding ASA's Beneish M-Score of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Biotechnology company?

A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PCI Biotech Holding ASA stock overvalued right now?

PCI Biotech Holding ASA (OSL:PCIB) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current Beneish M-Score is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Industry Healthcare Biotechnology

Comparable Companies VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ASX:CSL ALNY ONC XKRX:068270 INSM RVMD BNTX RPRX MRNA ROIV HKSE:01801 INCY HKSE:02269 SMMT OCSE:GMAB

Address Ullernchausseen 64, Oslo, NOR, N-0379

Website https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

6GF Score

Get the complete analysis for OSL:PCIB

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12

Price

View OSL:PCIB Analysis

See Beneish M-Score data for all stocks →